MGNX – Macrogenics Inc
MacroGenics, Inc.MGNX
$3.00Name : MacroGenics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $188,290,208.00
EPSttm : -1.57
MacroGenics, Inc.
$3.00
0.99%$0.03Float Short %
8.96
Margin Of Safety %
Put/Call OI Ratio
1.19
EPS Next Q Diff
-1.69
EPS Last/This Y
-1.23
EPS This/Next Y
-1.12
Price
3
Target Price
7.29
Analyst Recom
2.36
Performance Q
-27.18
Relative Volume
1.01
Beta
2.02
Ticker: MGNX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | MGNX | 3.18 | 0.67 | 1.25 | 7120 |
| 2024-12-20 | MGNX | 3.19 | 0.67 | 1.00 | 7119 |
| 2024-12-23 | MGNX | 3.23 | 1.15 | 1.43 | 4406 |
| 2024-12-24 | MGNX | 3.26 | 1.17 | 1.15 | 4558 |
| 2024-12-26 | MGNX | 3.25 | 1.17 | 0.00 | 4586 |
| 2024-12-27 | MGNX | 3.23 | 1.16 | 0.63 | 4600 |
| 2024-12-30 | MGNX | 3.23 | 1.16 | 0.63 | 4600 |
| 2024-12-31 | MGNX | 3.25 | 1.14 | 999.99 | 4632 |
| 2025-01-02 | MGNX | 3.31 | 1.15 | 0.00 | 4637 |
| 2025-01-03 | MGNX | 3.45 | 1.14 | 0.00 | 4640 |
| 2025-01-06 | MGNX | 3.48 | 1.13 | 0.11 | 4664 |
| 2025-01-07 | MGNX | 3.41 | 1.15 | 0.00 | 4655 |
| 2025-01-08 | MGNX | 3.35 | 1.15 | 8.40 | 4657 |
| 2025-01-09 | MGNX | 3.35 | 1.15 | 1.68 | 4657 |
| 2025-01-10 | MGNX | 3.18 | 1.18 | 0.00 | 4677 |
| 2025-01-13 | MGNX | 3.17 | 1.17 | 8.00 | 4669 |
| 2025-01-14 | MGNX | 3.04 | 1.19 | 19.00 | 4706 |
| 2025-01-15 | MGNX | 3.2 | 1.19 | 0.06 | 4720 |
| 2025-01-16 | MGNX | 3.04 | 1.19 | 1.43 | 4735 |
| 2025-01-17 | MGNX | 3 | 1.19 | 0.54 | 4740 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | MGNX | 3.18 | 26.2 | - | -1.38 |
| 2024-12-20 | MGNX | 3.19 | 26.2 | - | -1.38 |
| 2024-12-23 | MGNX | 3.23 | 26.2 | - | -1.38 |
| 2024-12-24 | MGNX | 3.26 | 26.2 | - | -1.38 |
| 2024-12-26 | MGNX | 3.26 | 26.2 | - | -1.38 |
| 2024-12-27 | MGNX | 3.23 | 26.2 | - | -1.38 |
| 2024-12-30 | MGNX | 3.23 | 26.2 | - | -1.38 |
| 2024-12-31 | MGNX | 3.24 | 26.2 | - | -1.38 |
| 2025-01-02 | MGNX | 3.31 | 26.2 | - | -1.38 |
| 2025-01-03 | MGNX | 3.46 | 26.2 | - | -1.38 |
| 2025-01-06 | MGNX | 3.48 | 26.2 | - | -1.38 |
| 2025-01-07 | MGNX | 3.41 | 26.2 | - | -1.38 |
| 2025-01-08 | MGNX | 3.35 | 26.2 | - | -1.38 |
| 2025-01-09 | MGNX | 3.35 | 26.2 | - | -1.38 |
| 2025-01-10 | MGNX | 3.18 | 26.2 | - | -1.38 |
| 2025-01-13 | MGNX | 3.17 | 26.2 | - | -1.38 |
| 2025-01-14 | MGNX | 3.05 | 26.2 | - | -1.38 |
| 2025-01-15 | MGNX | 3.19 | 26.2 | - | -1.38 |
| 2025-01-16 | MGNX | 3.03 | 26.2 | - | -1.38 |
| 2025-01-17 | MGNX | 3.00 | 26.2 | - | -1.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | MGNX | 0.00 | -8.76 | 9.01 |
| 2024-12-20 | MGNX | 0.00 | -8.76 | 9.01 |
| 2024-12-23 | MGNX | 0.00 | -8.76 | 9.01 |
| 2024-12-24 | MGNX | 0.00 | -8.76 | 9.01 |
| 2024-12-26 | MGNX | 0.00 | -8.76 | 9.33 |
| 2024-12-27 | MGNX | 0.00 | -8.76 | 9.33 |
| 2024-12-30 | MGNX | 0.00 | -8.70 | 9.33 |
| 2024-12-31 | MGNX | 0.00 | -8.70 | 9.33 |
| 2025-01-02 | MGNX | 0.00 | -8.70 | 9.33 |
| 2025-01-03 | MGNX | 0.00 | -8.70 | 9.33 |
| 2025-01-06 | MGNX | 0.00 | -8.80 | 9.33 |
| 2025-01-07 | MGNX | 0.00 | -8.80 | 9.33 |
| 2025-01-08 | MGNX | 0.00 | -8.80 | 9.33 |
| 2025-01-09 | MGNX | 0.00 | -8.80 | 9.33 |
| 2025-01-10 | MGNX | 0.00 | -8.80 | 9.33 |
| 2025-01-13 | MGNX | 0.00 | -8.80 | 8.96 |
| 2025-01-14 | MGNX | 0.00 | -8.80 | 8.96 |
| 2025-01-15 | MGNX | 0.00 | -8.80 | 8.96 |
| 2025-01-16 | MGNX | 0.00 | -8.80 | 8.96 |
| 2025-01-17 | MGNX | 0.00 | -8.80 | 8.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.9
Avg. EPS Est. Current Quarter
-0.55
Avg. EPS Est. Next Quarter
-0.79
Insider Transactions
Institutional Transactions
-8.8
Beta
2.02
Average Sales Estimate Current Quarter
32
Average Sales Estimate Next Quarter
14
Fair Value
Quality Score
40
Growth Score
38
Sentiment Score
2
Actual DrawDown %
91.8
Max Drawdown 5-Year %
-93.7
Target Price
7.29
P/E
Forward P/E
PEG
P/S
1.33
P/B
1.57
P/Free Cash Flow
EPS
-1.57
Average EPS Est. Cur. Y
-1.38
EPS Next Y. (Est.)
-2.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-69.07
Relative Volume
1.01
Return on Equity vs Sector %
-100.4
Return on Equity vs Industry %
-87.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.38
EBIT Estimation
MacroGenics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 339
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
stock quote shares MGNX – Macrogenics Inc Stock Price stock today
news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MGNX – Macrogenics Inc yahoo finance google finance
stock history MGNX – Macrogenics Inc invest stock market
stock prices MGNX premarket after hours
ticker MGNX fair value insiders trading